SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
OpenAI Restricts Astra AI Over Cyberattack Risks 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
NEW YORK, Feb. 23, 2018 -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ekso Bionics Holdings, Inc. (“Ekso Bionics” or the “Company”) (NASDAQ:EKSO).
On December 14, 2017, Ekso Bionics advised investors that “the Company’s internal control over financial reporting as of December 31, 2016 should no longer be relied upon and that a material weakness in the Company's internal control over financial reporting existed as of such date.” Then on December 27, 2017, the Company filed an amended annual report for 2016 and amended quarterly reports for the first three quarters of 2017.
On this news, Ekso Bionics’ share price declined.
If you invested in Ekso Bionics stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/EKSO. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].
CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
[email protected]
Telephone: (877) 247-4292 or (212) 983-9330
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
